Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Finance

Dementia Discovery Fund’s investments: Data Byte

June 18, 2021 11:32 PM UTC

Since its launch by SV Health Investors in 2015 to fund new thinking in Alzheimer’s and other neurological diseases, Dementia Discovery Fund (DDF) has funded one to four companies per year exploring new hypotheses, such as neuroinflammatory pathways, and new technologies, from RNA modulation to digital biomarkers.

At the halfway point, this year already is at the high end of that range, with the fund so far investing in four companies: immunology plays Therini Bio Inc. and Alchemab Therapeutics Ltd., digital biomarker company Cumulus Neuroscience, and most recently, Transine Therapeutics Ltd., which is developing long non-coding RNAs known as SINEUPs...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article